Investor Presentaiton
Innovation: 2022 in review
Key milestones delivered
Select clinical-stage readouts
Vaccine/Medicine
Shingrix
Phase/Indication
Status
Late stage
Marketed (ZOSTER-049); shingles (herpes zoster)
RSV OA vaccine (RSVPreF3)
Phase III (ARESVi-006); respiratory syncytial virus
Phase III (EAGLE-2 and EAGLE-3); uncomplicated
urinary tract infections
HIV
Infectious Disease
NM
gepotidacin
bepirovirsen
mRNA (CV0501)
mRNA (Flu-SV-mRNA)
N6LS (VH3810109)
otilimab
Phase llb (B-CLEAR); chronic hepatitis B
Phase I; COVID-19
Phase I; seasonal influenza
Phase Ila; HIV
Phase III (ContRAst programme); moderate to severe
rheumatoid arthritis
X
Oncology
Immunology
/ Respiratory
GSK
Select Business Development transactions
SIERRA
ONCOLOGY
SPER
THERAPEUTICS
Platform
ā Affinivax Mersana
Technology
WAVE
THERAPEUTICS
"T'EMPUS
CCL17 (GSK 3858279)
Phase I; osteoarthritis pain
momelotinib
Regulatory submission acceptance (US, EU); anaemia
of myelofibrosis
Blenrep
Phase III (DREAMM-3); relapsed/refractory multiple
myeloma
X
LIFE SCIENCES
Jemperli
Phase III (RUBY part 1); advanced or recurrent
endometrial cancer
11View entire presentation